|
1
|
American Cancer Society. Cancer Facts and
Figures 2014. Atlanta, Ga: American Cancer Society; 2014 Last
accessed May 21, 2014
|
|
2
|
Su Z, Graybill WS and Zhu Y: Detection and
monitoring of ovarian cancer. Clin Chim Acta. 415:341–345. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turk V, Stoka V, Vasiljeva O, et al:
Cysteine cathepsins: from structure, function and regulation to new
frontiers. Biochim Biophys Acta. 1824:68–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gocheva V and Joyce JA: Cysteine
cathepsins and the cutting edge of cancer invasion. Cell Cycle.
6:60–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mason SD and Joyce JA: Proteolytic
networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conus S and Simon HU: Cathepsins and their
involvement in immune responses. Swiss Med Wkly.
140:w130422010.PubMed/NCBI
|
|
7
|
Krepela E: Cysteine proteinases in tumor
cell growth and apoptosis. Neoplasma. 48:332–349. 2001.PubMed/NCBI
|
|
8
|
Mohamed MM and Sloane BF: Cysteine
cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer.
6:764–775. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duffy MJ: The role of proteolytic enzymes
in cancer invasion and metastasis. Clin Exp Metastasis. 10:145–155.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mullins SR, Sameni M, Blum G, Bogyo M,
Sloane BF and Moin K: Three-dimensional cultures modeling
premalignant progression of human breast epithelial cells: role of
cysteine cathepsins. Biol Chem. 393:1405–1416. 2012. View Article : Google Scholar
|
|
11
|
Rao Q, Cheng L, Xia QY, et al: Cathepsin K
expression in a wide spectrum of perivascular epithelioid cell
neoplasms (PEComas): a clinicopathological study emphasizing
extrarenal PEComas. Histopathology. 62:642–650. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jevnikar Z, Rojnik M, Jamnik P, Doljak B,
Fonovic UP and Kos J: Cathepsin H mediates the processing of talin
and regulates migration of prostate cancer cells. J Biol Chem.
288:2201–2209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakashima T, Yasumatsu R, Masuda M,
Clayman GL and Komune S: Prognostic value of cathepsin L and its
inhibitor headpin in oral squamous cell carcinoma. J Laryngol Otol.
126:1134–1137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bar-Sela G, Kaplan-Cohen V, Ilan N,
Vlodavsky I and Ben-Izhak O: Heparanase expression in
nasopharyngeal carcinoma inversely correlates with patient
survival. Histopathology. 49:188–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang W, Hu XX, Yang XZ, et al: Combined
detection of serum matrix metalloproteinase 9, acetyl heparinase
and cathepsin L in diagnosis of ovarian cancer. Chin J Cancer Res.
24:67–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sivaparvathi M, Yamamoto M, Nicolson GL,
et al: Expression and immunohistochemical localization of cathepsin
L during the progression of human gliomas. Clin Exp Metastasis.
14:27–34. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tumminello FM, Leto G, Pizzolanti G, et
al: Cathepsin D, B and L circulating levels as prognostic markers
of malignant progression. Anticancer Res. 16:2315–2319.
1996.PubMed/NCBI
|
|
18
|
Friedrich B, Jung K, Lein M, et al:
Cathepsins B, H, L and cysteine protease inhibitors in malignant
prostate cell lines, primary cultured prostatic cells and prostatic
tissue. Eur J Cancer. 35:138–144. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Svatek RS, Karam J, Karakiewicz PI, et al:
Role of urinary cathepsin B and L in the detection of bladder
urothelial cell carcinoma. J Urol. 179:478–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheahan K, Shuja S and Murnane MJ:
Cysteine protease activities and tumor development in human
colorectal carcinoma. Cancer Res. 49:3809–3814. 1989.PubMed/NCBI
|
|
21
|
Watanabe M, Higashi T, Hashimoto M, et al:
Elevation of tissue cathepsin B and L activities in gastric cancer.
Hepatogastroenterology. 34:120–122. 1987.PubMed/NCBI
|
|
22
|
Gabrijelcic D, Svetic B, Spaić D, et al:
Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem
Clin Biochem. 30:69–74. 1992.PubMed/NCBI
|
|
23
|
Niedergethmann M, Wostbrock B, Sturm JW,
Willeke F, Post S and Hildenbrand R: Prognostic impact of cysteine
proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Pancreas. 29:204–211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Casson AG, Wilson SM, McCart JA, et al:
ras mutation and expression of the ras-regulated genes osteopontin
and cathepsin L in human esophageal cancer. Int J Cancer.
72:739–745. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Samaiya M, Bakhshi S, Shukla AA, Kumar L
and Chauhan SS: Epigenetic regulation of cathepsin L expression in
chronic myeloid leukaemia. J Cell Mol Med. 15:2189–2199. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Luca A, Maiello MR, D’Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012.PubMed/NCBI
|
|
27
|
Zhang W, Ling D, Tan J, Zhang J and Li L:
Expression of urokinase plasminogen activator and plasminogen
activator inhibitor type-1 in ovarian cancer and its clinical
significance. Oncol Rep. 29:637–645. 2013.PubMed/NCBI
|
|
28
|
Goldman S and Shalev E: MMPS and TIMPS in
ovarian physiology and pathophysiology. Front Biosci. 9:2474–2483.
2004. View Article : Google Scholar : PubMed/NCBI
|
